ISM Products &
Services
OrthoProsta
ISM's client-specific OrthoProsta program is for
those suffering from or at high risk of prostate cancer.
Prostate cancer is one of the most
common forms of cancer in men and is one of the highest causes of cancer-related death
amongst men. Up to 90% of prostate cancer clients will suffer from some level of
impotence or incontinence following treatment or surgery and yet there are few therapies
currently available to help manage these side effects. Current treatments for tumors can
compromise sexual function and bladder control, whilst hormone therapies which control the
growth of tumors can make men more emotional, fatigued, subject to hot flushes and
dispirited. Aside from the physical side effects, depression and fatigue are common among
male cancer clients, contributing to non-compliance with therapy and poorer function in
the routines of daily life. These side effects are so significant that a large number of
men with early-stage disease elect to refuse, delay or cut-back on treatment of their
cancer in order to avoid the side effects of therapy.
The recommended initial program lasts for six months. Each
6-month program involves:
2 Aminomics blood tests/profiles and assessments
-
6-months disease specific type compound: ProstaBalance. During the period of the program, we will analyse the blood plasma Aminomics® Profiles to evaluate the amino acid composition of your blood. Using state of the art advanced HPLC laboratory technology, ISM® is able to effectively "blueprint" your Individual ISM© Profile. By better understanding the amino acid disturbances, ISM's medical and scientific team is able to design an Aminomics© Therapeutic Compound to target the probable cause. Custom compounds are then re-engineered on an ongoing basis to account for the results of your Profile.
-
6-months protein: ProComp
6-months multi-supplement: NuComp
6-months flax seed: FS Comp
All ISMŽ products are compounded from highly bioavailable,
zero-pathogen, pharmaceutical grade component nutraceuticals.
|
